LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Troponin Assays Evaluated for Acute MI

By LabMedica International staff writers
Posted on 05 Jun 2018
Print article
Image: The PATHFAST compact immunoanalyzer used for measuring cardiac troponin (Photo courtesy of Mitsubishi Chemical Europe).
Image: The PATHFAST compact immunoanalyzer used for measuring cardiac troponin (Photo courtesy of Mitsubishi Chemical Europe).
In hospital laboratories and in point-of-care testing, cardiac troponin measurements are achieved by various assays, including “contemporary,” “sensitive” and “highly-sensitive” assays.

Due to the absence of standardization, troponin results cannot be transferred from one assay to another, and individual cut-offs must be strictly used in the context of the troponin assay for which they were determined.

Scientists from several intuitions collaborated with Cochin Hospital (Paris, France) and compared the use of nine different cardiac troponin (cTn) assays (two cTnT and seven cTnI) for the diagnosis of non-ST elevation acute myocardial infarction (NSTEMI) in a single multi-center population. The study was conducted in 13 French hospitals: nine centers were involved in patient inclusion and sample collection, with four additional centers involved in the measurement of troponin only and was performed between April 2014 and November 2015. The study included 158 patients (mean age 60 ±17 years), including 23 patients (14%) with NSTEMI.

The teams found that the analytical comparison highlighted a large heterogeneity of cTn assays, as reflected by percentages of patients with detectable cTn, correlation coefficients, Passing-Bablok comparisons and concordance coefficients. Correlations within cTnI assays were good and correlation within cTnT assays was excellent. Diagnostic performances demonstrated that each cTn assay has specific threshold values. Furthermore, some assays HS-cTnI and T, cTnI-Pathfast and cTnI-Centaur indicated high sensitivity and negative predictive value using the limit of detection (LoD) diagnostic strategy.

The authors concluded that all nine cTn assays indicated overall good diagnostic performances for the diagnosis of NSTEMI in emergency departments when the recommended algorithm based on the variation of cTn value between two measurements at admission and three hours later was used. The study was published in the July 2018 issue of the journal Practical Laboratory Medicine.

Related Links:
Cochin Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more